Anti-Human EFNB2 Recombinant Antibody (2B1) (CAT#: TAB-389MZ)

Figure 1 Determination of the specificity of the scFv anti-ephrin B2 selected against different ephrin B by immunoblot.

Figure 2 Study Blocking the Binding of Ephrin B2 to Eph B4.

Graph showing the percent of binding of ephrin B2 to Eph B4. Binding inhibition tests of ephrin B2 to Eph B4 in the presence of scFv anti-ephrin B2 by surface plasmon resonance. Serial dilutions of scFv B11 (•) or 2B1 (∘) were mixed with ephrin B2 and injected over Eph B4 immobilized on a chip. The relative amount of ephrin B2 bound to Eph B4 was measured immediately after injection of each sample and plotted as a function of the concentration of scFv.

Figure 3 Inhibitory Effect of B11 and 2B1 on Tubular Structures Formation in Vitro by Endothelial Cells HUVEC in Matrigel.

Photomicrographs (magnification 4×) representative of tubules formation at 6 hours of cultivate HUVEC cells on Matrigel in the presence of B11, 2B1 or an irrelevant scFv as negative control (C−). As a positive control we used VEGF. The graph shows the quantification of tubules formation. Each treatment was repeated at least three times and corresponding values (mean+/−standard deviation) are plotted as percentage of the tubules formed in the presence of the antibodies tested related to the control without any treatment. *=p<0.0001.

Figure 4 Analysis of the of Cell Lateral Migration Inhibition by In Vitro Wound Healing Assay.

HUVEC cells were grown to confluence and a wound was performed in the cell monolayer. Then, cells were incubated in serum free medium in the absence (control) or in presence of VEGF as migration stimulus. The lateral migration of the cells was monitored for 24 hours in the presence of the scFv anti-ephrin B2, B11 or 2B1, or an irrelevant scFv as negative control.

Figure 5 Inhibition of Tumour Growth in Mice Xenograft with Pancreatic Carcinoma Cells (BxPC3) and Treated with B11 or 2B1.

The graph shows the average tumour volumes and standard deviation at each point for each group (n=8) treated with 20 mg/kg of B11 (┐), 2B1 (▪) or untreated (C−) (♦).